Charles Rudin
Charles Rudin
Chief, Thoracic Oncology, Memorial Sloan Kettering Cancer Center
Verified email at - Homepage
Cited by
Cited by
Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer
H Borghaei, L Paz-Ares, L Horn, DR Spigel, M Steins, NE Ready, ...
New England Journal of Medicine 373 (17), 1627-1639, 2015
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ...
Nature genetics 51 (2), 202-206, 2019
Akt stimulates aerobic glycolysis in cancer cells
RL Elstrom, DE Bauer, M Buzzai, R Karnauskas, MH Harris, DR Plas, ...
Cancer research 64 (11), 3892-3899, 2004
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs
MG Kris, BE Johnson, LD Berry, DJ Kwiatkowski, AJ Iafrate, II Wistuba, ...
Jama 311 (19), 1998-2006, 2014
Efficacy and safety of vismodegib in advanced basal-cell carcinoma
A Sekulic, MR Migden, AE Oro, L Dirix, KD Lewis, JD Hainsworth, ...
New England Journal of Medicine 366 (23), 2171-2179, 2012
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma
DD Von Hoff, PM LoRusso, CM Rudin, JC Reddy, RL Yauch, R Tibes, ...
New England Journal of Medicine 361 (12), 1164-1172, 2009
Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449
CM Rudin, CL Hann, J Laterra, RL Yauch, CA Callahan, L Fu, T Holcomb, ...
New England Journal of Medicine 361 (12), 1173-1178, 2009
Genetic Variants in the UDP-glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of Irinotecan
F Innocenti, SD Undevia, L Iyer, P Xian Chen, S Das, M Kocherginsky, ...
Journal of Clinical Oncology 22 (8), 1382-1388, 2004
Molecular determinants of response to anti–programmed cell death (PD)-1 and anti–programmed death-ligand 1 (PD-L1) blockade in patients with non–small-cell lung cancer profiled …
H Rizvi, F Sanchez-Vega, K La, W Chatila, P Jonsson, D Halpenny, ...
Journal of clinical oncology 36 (7), 633, 2018
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung AdenocarcinomaSTK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant LUAC
F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ...
Cancer discovery 8 (7), 822-835, 2018
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer
CM Rudin, S Durinck, EW Stawiski, JT Poirier, Z Modrusan, DS Shames, ...
Nature genetics 44 (10), 1111-1116, 2012
Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma
RL Yauch, GJP Dijkgraaf, B Alicke, T Januario, CP Ahn, T Holcomb, ...
Science 326 (5952), 572-574, 2009
Pneumonitis in patients treated with anti–programmed death-1/programmed death ligand 1 therapy
J Naidoo, X Wang, KM Woo, T Iyriboz, D Halpenny, J Cunningham, ...
Journal of Clinical Oncology 35 (7), 709, 2017
Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer
MD Hellmann, T Nathanson, H Rizvi, BC Creelan, F Sanchez-Vega, ...
Cancer cell 33 (5), 843-852. e4, 2018
Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non–Small Cell Lung CancerCombinatorial Epigenetic Therapy for Lung Cancer
RA Juergens, J Wrangle, FP Vendetti, SC Murphy, M Zhao, B Coleman, ...
Cancer discovery 1 (7), 598-607, 2011
DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration
H Kaneko, S Dridi, V Tarallo, BD Gelfand, BJ Fowler, WG Cho, ...
Nature 471 (7338), 325-330, 2011
Lung cancer in never smokers: clinical epidemiology and environmental risk factors
JM Samet, E Avila-Tang, P Boffetta, LM Hannan, S Olivo-Marston, ...
Clinical cancer research 15 (18), 5626-5645, 2009
Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
CM Rudin, JT Poirier, LA Byers, C Dive, A Dowlati, J George, JV Heymach, ...
Nature Reviews Cancer 19 (5), 289-297, 2019
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors
L Gandhi, DR Camidge, MR De Oliveira, P Bonomi, D Gandara, D Khaira, ...
Journal of clinical oncology 29 (7), 909, 2011
Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid TumorsGDC-0449 Treatment of Advanced or …
PM LoRusso, CM Rudin, JC Reddy, R Tibes, GJ Weiss, MJ Borad, ...
Clinical cancer research 17 (8), 2502-2511, 2011
The system can't perform the operation now. Try again later.
Articles 1–20